We are live on ! Find out more
NRSNW icon

NeuroSense Therapeutics Warrant
NRSNW

2 hedge funds and large institutions have $41.3K invested in NeuroSense Therapeutics Warrant in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more capital invested

Capital invested by funds: $16.1K → $41.3K (+$25.2K)

0.12% less ownership

Funds ownership: 0.4% → 0.28% (-0.12%)

33% less funds holding

Funds holding: 3 → 2 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
-$2.05K
2
CS
Clear Street
New York
-$809
3
UBS Group
UBS Group
Switzerland
-$535
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
1
Clear Street
New York
$40.4K -$809 -2,074 -3%
UBS Group
2
UBS Group
Switzerland
$932 -$535 -1,371 -48%
WAM
3
Warberg Asset Management
Illinois
– -$2.05K -10,000 Closed

NRSNW Hedge Fund Activity: Q2 2025 in Review

2 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q2 2025, worth a combined $41.3K — up 156% from $16.1K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of NRSNW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.

The largest seller was Warberg Asset Management, exiting entirely with an estimated $2.05K sold.

  • 2 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q2 2025, down from 3 in Q1 2025.
  • Funds reported $41.3K of NeuroSense Therapeutics Warrant stock for Q2 2025, up 156% quarter-over-quarter.
  • 0 funds opened new NeuroSense Therapeutics Warrant positions in Q2 2025 and 1 closed out, a net change of -1 holder.
  • The largest NeuroSense Therapeutics Warrant seller in Q2 2025 was Warberg Asset Management, an estimated $2.05K sold.

Based on aggregated 13F filings for Q2 2025.